Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis
- PMID: 22990653
- PMCID: PMC3493765
- DOI: 10.1038/bjc.2012.421
Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis
Abstract
Background: Identifying various pretreatment factors that predict chemotherapy-induced toxicity in colorectal cancer (CRC) patients undergoing treatment for their disease is crucial to optimising patient care.
Methods: Seventy-three patients received adjuvant 5-fluorouracil (5FU)/leucovorin using either the Mayo Clinic (n=42) or a weekly schedule (n=31) and evaluated for clinical toxicity. Pretreatment blood analysis included measures of plasma uracil and dihydrouracil, peripheral blood mononuclear cell (PBMNC) telomere length (TL), standard biochemistry and cell differential analysis. On the first day of treatment 5FU-pharmacokinetic variables of area under the curve, half life and clearance were also measured. These variables together with age and gender were used in univariate and multivariate analysis as predictors of clinical toxicity.
Results: For the Mayo schedule the primary toxicities were neutropenia (69%), mucositis (58%) and leukopenia (46%), with 70% of patients presenting with haematological toxicity ≥grade 1 (neutropenia and/or leukopenia). Multivariate analysis showed that haematological toxicity was predicted by short TL, high platelet lymphocyte ratio (PLR) and low neutrophil count (R(2)=0.38, P<0.0006), whereas mucositis was predicted by age, TL and PLR (R(2)=0.34, P<0.001). For the weekly schedule diarrhoea predominated (16%), with female gender as the only predictive factor. Although measures of uracil metabolism correlated well with 5FU metabolism (r=0.45-0.49), they did not indicate abnormal pyrimidine metabolism in this cohort and not surprisingly failed to predict for 5FU toxicity.
Conclusion: Short TL of PBMNC and an increased PLR were strong predictors of mucositis and haematological toxicity in CRC patients undergoing 5FU treatment in the adjuvant setting.
Figures

Similar articles
-
Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?Eur J Cancer. 2014 Nov;50(17):2966-74. doi: 10.1016/j.ejca.2014.08.017. Epub 2014 Sep 26. Eur J Cancer. 2014. PMID: 25266443 Clinical Trial.
-
Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin.Eur J Cancer. 2007 Jan;43(2):459-65. doi: 10.1016/j.ejca.2006.09.017. Epub 2006 Nov 13. Eur J Cancer. 2007. PMID: 17097873
-
Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid.Anticancer Res. 2002 Nov-Dec;22(6B):3449-55. Anticancer Res. 2002. PMID: 12552938
-
Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer.Br J Cancer. 2009 May 19;100(10):1549-57. doi: 10.1038/sj.bjc.6605052. Epub 2009 Apr 21. Br J Cancer. 2009. PMID: 19384296 Free PMC article. Clinical Trial.
-
[Levofolinate and fluorouracil combination therapy].Nihon Yakurigaku Zasshi. 2001 Sep;118(3):211-8. doi: 10.1254/fpj.118.211. Nihon Yakurigaku Zasshi. 2001. PMID: 11577462 Review. Japanese.
Cited by
-
Gastrointestinal Cancers with Consideration of DPD and UGT1A1 Plasma Levels: Chemotherapy-Related Toxicity.Life (Basel). 2025 Jul 4;15(7):1071. doi: 10.3390/life15071071. Life (Basel). 2025. PMID: 40724574 Free PMC article.
-
Mitochondrial Factor C20orf7 Facilitates the EMT-Mediated Cancer Cell Migration and the Proliferation of Colon Cancer In Vitro and In Vivo.Genes (Basel). 2022 Nov 14;13(11):2111. doi: 10.3390/genes13112111. Genes (Basel). 2022. PMID: 36421786 Free PMC article.
-
Role of the transient receptor potential melastatin 4 in inhibition effect of arsenic trioxide on the tumor biological features of colorectal cancer cell.PeerJ. 2024 Jun 4;12:e17559. doi: 10.7717/peerj.17559. eCollection 2024. PeerJ. 2024. PMID: 38854798 Free PMC article.
-
Monitoring of telomere dynamics in peripheral blood leukocytes in relation to colorectal cancer patients' outcomes.Front Oncol. 2022 Sep 20;12:962929. doi: 10.3389/fonc.2022.962929. eCollection 2022. Front Oncol. 2022. PMID: 36203452 Free PMC article.
-
Predicting Severe Haematological Toxicity in Gastrointestinal Cancer Patients Undergoing 5-FU-Based Chemotherapy: A Bayesian Network Approach.Cancers (Basel). 2023 Aug 22;15(17):4206. doi: 10.3390/cancers15174206. Cancers (Basel). 2023. PMID: 37686482 Free PMC article.
References
-
- Ackland SP, Garg MB, Dunstan RH (1997) Simultaneous determination of dihydroflurouracil and 5-fluorouracil in plasma by high-performance liquid chromatography. Anal Biochem 246: 79–85 - PubMed
-
- Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G, Serna-Thomé M, Flores-Estrada D, Diaz-Romero C, Rodríguez CM, Martínez L, Sánchez-Lara K (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 10: 50. - PMC - PubMed
-
- Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JCW, Gordon-Smith EC (1998) Progressive telomere shortening in aplastic anemia. Blood 91: 3582–3592 - PubMed
-
- Barasch A, Peterson DE (2003) Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 39: 91–100 - PubMed
-
- Blackburn EH (2005) Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett 579: 859–862 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical